Menu
Recruiting NCT05912647

Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes

No phase Interventional Diabetes Diabetes Type 2

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: MTM, CHW.
Who it may be relevant to
Registry conditions: Diabetes, Diabetes Type 2. Basic parameters: 18 years — 90 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Multiphase Optimization Strategy to Enhance Diabetes Management Interventions for Patients With Uncontrolled Diabetes

Overview

The purpose of the study is to learn about the best way to enhance pharmacy-related care for diabetes self-management. This research is being done because we want to improve use of medicines and diabetes management among adults with type 2 diabetes and find out which of type of support may improve diabetes self-management for adults. Participants will be assigned to one of 4 groups, and will either: * receive care as usual; or, * receive added medicine management support from a pharmacist; or, * receive support from a Community Health Worker (CHW) to address life challenges; or, * receive both the pharmacist medicine management and the CHW support

Detailed description

For the ENRxICH intervention, all participants will receive usual care for their diabetes management. Participants will be randomized to one of four treatment conditions: 1. Usual Care, 2. Medication Therapy Management (MTM) Optimizing Medication Therapy (ON), 3. Community Health Worker (CHW) addressing social determinants of health (SDOH) and diabetes and medicine misperceptions (ON), or 4. both MTM Optimizing Medication Therapy and CHW Addressing SDOH and diabetes and medicine misperceptions for 6 months.

Subjects randomized to the treatment conditions including MTM will receive a minimum of five pharmacist-delivered Medication Therapy Management (MTM) sessions with a pharmacist, two in the first month, one medication review each in the second and third month, and a final medication review at 6 months.

Subjects randomized to the treatment conditions including CHW support addressing social determinants of health (SDOH) which will involve meeting with the CHW for a formal, standardized 2-hour assessment of five common SDOH barriers related to diabetes management, (1) food insecurity, (2) transportation, (3) prescription medication assistance, (4) access to diabetes education, and (5) physical activity resources (See Table 6). After the initial session at the participant's home (or another community location), the participant will have the option of continuing to work with the CHW to address barriers for the intervention duration. CHW support will also address diabetes and medicine misperceptions by completing a series of phone calls with the subject to provide information about managing diabetes and medicines, discuss cultural health misperceptions, share medication adherence experiences, and provide social support over the phone.

Interventions

  • Behavioral MTM
    Participants will receive added medicine management support from a pharmacist. This will involve one 60-minute session with the pharmacist either in-person or over the phone and at least four 30-minute follow-up sessions with the pharmacist over the phone.
  • Behavioral CHW
    Participants will receive support from a Community Health Worker (CHW) to address life challenges that might be affecting their health and diabetes and to discuss diabetes beliefs and concerns. This will involve one \~30-minute phone call with the CHW to discuss needs and a 2-hour session with the CHW in-person for a comprehensive assessment. Participants will also receive \~10, 15 to 30-minute calls from the CHW to discuss diabetes beliefs and concerns.

Primary outcome measures

  • Change in mean hemoglobin A1c score [Time frame: Baseline to 6 months]
  • Change in mean hemoglobin A1c score [Time frame: Baseline to 12 months]
Secondary outcome measures (2)
  • Change in medication adherence - medication refill [Time frame: 6 months and 12 months]
  • Mean scores on the Adherence to Refills and Medications Scale for Diabetes [Time frame: 6 months and 12 months]

Eligibility criteria

Inclusion criteria

  • Men and women ages 18-90 with diagnosed type 2 diabetes who speak and understand English or Spanish.
  • Taking at least one oral or injectable diabetes medication
  • HbA1c ≥ 7.5% based on point of care test.
  • Will reside in the geographical area throughout the study period.
  • Have access to a phone during the study period.
  • Willing to attend all orientation/training sessions.

Exclusion criteria

  • Having a caregiver who is the main decision maker in self-management.
  • Participating in another lifestyle, or medication adherence program.
  • Participated in standard MTM/MTM-related intervention in the last 6 months.
  • Women who are pregnant or plan to get pregnant in the next 6 months.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Health services research

Study locations

United States · 1 center
  • University of Wisconsin — Madison

Publications

  • Shiyanbola OO, Maurer MA, Piper ME, Bolt D, Sharp LK, Ouayogode MH, Fisher E. Optimizing diabetes management interventions for Black and Hispanic adults using the multiphase optimization strategy: Protocol for a randomized mixed methods factorial trial. Contemp Clin Trials. 2025 Feb;149:107804. doi: 10.1016/j.cct.2024.107804. Epub 2025 Jan 4. PMID 39761827

Identifiers

NCT: NCT05912647 · 2023-0780 · 1R01DK136690-01 · PHARM/PHARMACY · Protocol Version 5/6/26

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗